These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15069309)

  • 21. Intermittent androgen deprivation therapy for prostate cancer.
    Rashid MH; Chaudhary UB
    Oncologist; 2004; 9(3):295-301. PubMed ID: 15169984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients and partners lack knowledge of androgen deprivation therapy side effects.
    Walker LM; Tran S; Wassersug RJ; Thomas B; Robinson JW
    Urol Oncol; 2013 Oct; 31(7):1098-105. PubMed ID: 22285008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
    BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy complications.
    Allan CA; Collins VR; Frydenberg M; McLachlan RI; Matthiesson KL
    Endocr Relat Cancer; 2014 Aug; 21(4):T119-29. PubMed ID: 24872511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?
    Wibowo E; Wassersug RJ; Robinson JW; Matthew A; McLeod D; Walker LM
    Clin Genitourin Cancer; 2019 Jun; 17(3):e408-e419. PubMed ID: 30745202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
    Flaig TW; Glodé LM
    Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormone replacement therapy in prostate cancer: side effects and their management].
    Bonniol R; Timsit MO
    Prog Urol; 2012 Nov; 22(14):881-5. PubMed ID: 23101960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy.
    Hanisch LJ; Gehrman PR
    Aging Male; 2011 Dec; 14(4):243-8. PubMed ID: 21627561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Trazodone: a new selective approach to the treatment of hot flashes induced by androgen deprivation in prostate carcinoma?].
    González SV; Puig FM; Martí SS; Sánchez MV; Capellán Mdel M; Martos MA
    Actas Urol Esp; 2009 Jun; 33(6):635-8. PubMed ID: 19711746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 36. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
    Quella SK; Loprinzi CL; Sloan J; Novotny P; Perez EA; Burch PA; Antolak SJ; Pisansky TM
    J Urol; 1999 Jul; 162(1):98-102. PubMed ID: 10379749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of hot flushes for men treated with androgen deprivation therapy for prostate cancer: a survey of UK practice.
    Kinnaird W; Mehta A; Guo C; Payne H; Jenkins V; Catt S
    Acupunct Med; 2021 Aug; 39(4):394-395. PubMed ID: 33023298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.